[144] DexCom, Inc. SEC Filing

Rhea-AI Filing Summary

DexCom Form 144 summary: This notice reports proposed sales of 1,466 shares of DexCom common stock to be executed through Morgan Stanley Smith Barney LLC on 09/04/2025 on NASDAQ, with an aggregate market value listed at $117,280.00. The filings show the same filer, Sadie Stern, sold 1,466 shares on 07/28/2025 for $130,459.34 and 1,466 shares on 06/26/2025 for $124,697.96 during the past three months. The securities to be sold were originally acquired as restricted stock from the issuer on 12/15/2023 (978 shares) and 11/19/2023 (488 shares). The filer affirms no undisclosed material adverse information.

Positive

• Required Rule 144 details provided including broker, share counts, acquisition dates, and recent sales
• Origin of shares disclosed as restricted stock acquired from the issuer on specific dates

Negative

• Insider sales reported (1,466 shares planned; 1,466 shares sold 07/28/2025; 1,466 shares sold 06/26/2025)
• Aggregate market value noted for the planned sale is $117,280.00, indicating insider liquidity activity

Insights

Financial Analyst

TL;DR: Routine insider sale notice showing limited share blocks sold via a broker; not a material financing or corporate change.

The Form 144 documents proposed and recent sales by an individual identified as Sadie Stern. The notice lists a planned sale of 1,466 shares with an aggregate market value of $117,280 executed through Morgan Stanley Smith Barney on NASDAQ. Two prior sales in June and July 2025 are reported with gross proceeds disclosed. Acquisition dates and that the shares originated as restricted stock are provided, which supports that these are controlled dispositions of previously granted equity rather than open-market issuances. Impact appears informational rather than company-altering.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 mechanics; shows compliance with sale aggregation and broker execution requirements.

The filing supplies the required details under Rule 144: broker name, share counts, acquisition method, and recent related sales. The signer represents absence of undisclosed material adverse facts and notes plan/trading-instruction fields are present though not populated. From a governance perspective, the form documents insider liquidity actions and demonstrates procedural compliance; it does not disclose changes in management, control, or corporate policy.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1466	117280.00	392155265	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/15/2023	Restricted Stock	ISSUER			978	12/15/2023	Not Applicable
Common	11/19/2023	Restricted Stock	ISSUER			488	11/19/2023	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SADIE STERN 6340 Sequence Drive San Diego CA 92121	Common	07/28/2025	1466	130459.34
SADIE STERN 6340 Sequence Drive San Diego CA 92121	Common	06/26/2025	1466	124697.96

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does DexCom's (DXCM) Form 144 filed here disclose?

The filing discloses a proposed sale of 1,466 shares via Morgan Stanley Smith Barney on NASDAQ (09/04/2025) with aggregate market value $117,280.00 and two prior sales in June and July 2025.

Who is the seller named in this Form 144 for DXCM?

The seller identified in the document is Sadie Stern, with recent sales and the proposed sale described in the filing.

How were the shares being sold originally acquired?

The securities were acquired as restricted stock from the issuer on 12/15/2023 (978 shares) and 11/19/2023 (488 shares).

What broker is handling the proposed sale in this Form 144?

The broker named for the proposed sale is Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004.

What proceeds were realized from recent insider sales reported in the filing?

Proceeds listed: $130,459.34 for the 07/28/2025 sale and $124,697.96 for the 06/26/2025 sale (each for 1,466 shares).